Acarbose (sulfate)

• Description:

  Acarbose (BAY g 5421) sulfate, antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM) . Acarbose sulfate can potentiate the hypoglycemic effects of sulfonylureas or insulin[1][2][3].

• Product Name Alternative:

  Bay-g 5421 sulfate

• UNSPSC:

  12352005

• Target:

  Glycosidase

• Type:

  Natural Products

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Metabolic Disease; Cardiovascular Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/acarbose-sulfate.html

• Solubility:

  10 mM in H2O

• Smiles:

  O[C@@H]1C(CO)=C[C@H](N[C@H]2[C@H](O)[C@@H](O)[C@@H](O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O)O[C@@H]2C)[C@H](O)[C@H]1O.O=S(O)(O)=O

• Molecular Formula:

  C25H45NO22S

• Molecular Weight:

  743.68

• References & Citations:

  [1]Zhang Q, et al. Acarbose Reduces Blood Glucose by Activating miR-10a-5p and miR-664 in Diabetic Rats. PLoS One. 2013 Nov 18;8 (11) :e79697.|[2]Chan KC, et al. Pleiotropic effects of acarbose on atherosclerosis development in rabbits are mediated via upregulating AMPK signals. Sci Rep. 2016 Dec 7;6:3864|[3]Hanefeld M, et al. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits [published correction appears in Expert Rev Cardiovasc Ther. 2009 Mar;7 (3) :330]. Expert Rev Cardiovasc Ther. 2008;6 (2) :153-163.|[4]Yee HS, et al. A review of the safety and efficacy of acarbose in diabetes mellitus. Pharmacotherapy. 1996;16 (5) :792-805.|[5]Oki T, et al. Evaluation of alpha-glucosidase inhibition by using an immobilized assay system. Biol Pharm Bull. 2000;23 (9) :1084-1087.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Natural Products

• Clinical Information:

  Launched

• CAS Number:

  [1221158-13-9]